Case Report: Response to crizotinib treatment in a patient with advanced non-small cell lung cancer with LDLR-ROS1 fusion
C-ros oncogene 1 (ROS1) fusion is a pathogenic driver gene in non-small cell lung cancer (NSCLC). Currently, clinical guidelines from the National Comprehensive Cancer Network (NCCN) have recommended molecular pathologic tests for patients with NSCLC, including the detection of the ROS1 gene. Crizot...
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2023-04-01
|
| Series: | Frontiers in Oncology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fonc.2023.1169876/full |
| _version_ | 1797843754914152448 |
|---|---|
| author | Yun Shu Zhouyu Wang Zhouyu Wang Hongjuan Shang Wei Le Yan Lei Yan Lei Longzhang Huang Liming Tao Jun Chen Jing Li Jing Li |
| author_facet | Yun Shu Zhouyu Wang Zhouyu Wang Hongjuan Shang Wei Le Yan Lei Yan Lei Longzhang Huang Liming Tao Jun Chen Jing Li Jing Li |
| author_sort | Yun Shu |
| collection | DOAJ |
| description | C-ros oncogene 1 (ROS1) fusion is a pathogenic driver gene in non-small cell lung cancer (NSCLC). Currently, clinical guidelines from the National Comprehensive Cancer Network (NCCN) have recommended molecular pathologic tests for patients with NSCLC, including the detection of the ROS1 gene. Crizotinib is a small molecule tyrosine kinase inhibitor of anaplastic lymphoma kinase (ALK), ROS1, and mesenchymal-epithelial transition (MET). In recent years, the efficacy of crizotinib in NSCLC patients with ROS1 fusion has been reported. Here, a 77-year-old woman was diagnosed with stage IVA lung adenocarcinoma harboring a novel low-density lipoprotein receptor (LDLR)-ROS1 fusion variant. This novel LDLR-ROS1 fusion was identified by targeted DNA next-generation sequencing (NGS) panel and then verified by RNA fusion panel based on amplicon sequencing. This patient benefited from subsequent crizotinib therapy and achieved progression-free survival of 15 months without significant toxic symptoms. Our case report recommended a promising targeted therapeutic option for patients with metastatic NSCLC with LDLR-ROS1 fusion and highlighted the importance of genetic testing for accurate treatment. |
| first_indexed | 2024-04-09T17:11:06Z |
| format | Article |
| id | doaj.art-1921a906d0cb4e7b90f886b468f1a66d |
| institution | Directory Open Access Journal |
| issn | 2234-943X |
| language | English |
| last_indexed | 2024-04-09T17:11:06Z |
| publishDate | 2023-04-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Oncology |
| spelling | doaj.art-1921a906d0cb4e7b90f886b468f1a66d2023-04-20T05:53:59ZengFrontiers Media S.A.Frontiers in Oncology2234-943X2023-04-011310.3389/fonc.2023.11698761169876Case Report: Response to crizotinib treatment in a patient with advanced non-small cell lung cancer with LDLR-ROS1 fusionYun Shu0Zhouyu Wang1Zhouyu Wang2Hongjuan Shang3Wei Le4Yan Lei5Yan Lei6Longzhang Huang7Liming Tao8Jun Chen9Jing Li10Jing Li11Department of Medical Oncology, Third People’s Hospital of Jiujiang City, Jiujiang, ChinaDepartment of Medical Affairs, Berry Oncology Corporation, Beijing, ChinaFujian Key Laboratory of Advanced Technology for Cancer Screening and Early Diagnosis, Fuzhou, ChinaDepartment of Medical Oncology, Third People’s Hospital of Jiujiang City, Jiujiang, ChinaDepartment of Medical Oncology, Third People’s Hospital of Jiujiang City, Jiujiang, ChinaDepartment of Medical Affairs, Berry Oncology Corporation, Beijing, ChinaFujian Key Laboratory of Advanced Technology for Cancer Screening and Early Diagnosis, Fuzhou, ChinaDepartment of Medical Oncology, Third People’s Hospital of Jiujiang City, Jiujiang, ChinaDepartment of Medical Oncology, Third People’s Hospital of Jiujiang City, Jiujiang, ChinaDepartment of Medical Oncology, Third People’s Hospital of Jiujiang City, Jiujiang, ChinaDepartment of Medical Affairs, Berry Oncology Corporation, Beijing, ChinaFujian Key Laboratory of Advanced Technology for Cancer Screening and Early Diagnosis, Fuzhou, ChinaC-ros oncogene 1 (ROS1) fusion is a pathogenic driver gene in non-small cell lung cancer (NSCLC). Currently, clinical guidelines from the National Comprehensive Cancer Network (NCCN) have recommended molecular pathologic tests for patients with NSCLC, including the detection of the ROS1 gene. Crizotinib is a small molecule tyrosine kinase inhibitor of anaplastic lymphoma kinase (ALK), ROS1, and mesenchymal-epithelial transition (MET). In recent years, the efficacy of crizotinib in NSCLC patients with ROS1 fusion has been reported. Here, a 77-year-old woman was diagnosed with stage IVA lung adenocarcinoma harboring a novel low-density lipoprotein receptor (LDLR)-ROS1 fusion variant. This novel LDLR-ROS1 fusion was identified by targeted DNA next-generation sequencing (NGS) panel and then verified by RNA fusion panel based on amplicon sequencing. This patient benefited from subsequent crizotinib therapy and achieved progression-free survival of 15 months without significant toxic symptoms. Our case report recommended a promising targeted therapeutic option for patients with metastatic NSCLC with LDLR-ROS1 fusion and highlighted the importance of genetic testing for accurate treatment.https://www.frontiersin.org/articles/10.3389/fonc.2023.1169876/fulladvanced non-small cell lung cancerc-ros oncogene 1LDLR-ROS1 fusioncrizotinibnext-generation sequencing |
| spellingShingle | Yun Shu Zhouyu Wang Zhouyu Wang Hongjuan Shang Wei Le Yan Lei Yan Lei Longzhang Huang Liming Tao Jun Chen Jing Li Jing Li Case Report: Response to crizotinib treatment in a patient with advanced non-small cell lung cancer with LDLR-ROS1 fusion Frontiers in Oncology advanced non-small cell lung cancer c-ros oncogene 1 LDLR-ROS1 fusion crizotinib next-generation sequencing |
| title | Case Report: Response to crizotinib treatment in a patient with advanced non-small cell lung cancer with LDLR-ROS1 fusion |
| title_full | Case Report: Response to crizotinib treatment in a patient with advanced non-small cell lung cancer with LDLR-ROS1 fusion |
| title_fullStr | Case Report: Response to crizotinib treatment in a patient with advanced non-small cell lung cancer with LDLR-ROS1 fusion |
| title_full_unstemmed | Case Report: Response to crizotinib treatment in a patient with advanced non-small cell lung cancer with LDLR-ROS1 fusion |
| title_short | Case Report: Response to crizotinib treatment in a patient with advanced non-small cell lung cancer with LDLR-ROS1 fusion |
| title_sort | case report response to crizotinib treatment in a patient with advanced non small cell lung cancer with ldlr ros1 fusion |
| topic | advanced non-small cell lung cancer c-ros oncogene 1 LDLR-ROS1 fusion crizotinib next-generation sequencing |
| url | https://www.frontiersin.org/articles/10.3389/fonc.2023.1169876/full |
| work_keys_str_mv | AT yunshu casereportresponsetocrizotinibtreatmentinapatientwithadvancednonsmallcelllungcancerwithldlrros1fusion AT zhouyuwang casereportresponsetocrizotinibtreatmentinapatientwithadvancednonsmallcelllungcancerwithldlrros1fusion AT zhouyuwang casereportresponsetocrizotinibtreatmentinapatientwithadvancednonsmallcelllungcancerwithldlrros1fusion AT hongjuanshang casereportresponsetocrizotinibtreatmentinapatientwithadvancednonsmallcelllungcancerwithldlrros1fusion AT weile casereportresponsetocrizotinibtreatmentinapatientwithadvancednonsmallcelllungcancerwithldlrros1fusion AT yanlei casereportresponsetocrizotinibtreatmentinapatientwithadvancednonsmallcelllungcancerwithldlrros1fusion AT yanlei casereportresponsetocrizotinibtreatmentinapatientwithadvancednonsmallcelllungcancerwithldlrros1fusion AT longzhanghuang casereportresponsetocrizotinibtreatmentinapatientwithadvancednonsmallcelllungcancerwithldlrros1fusion AT limingtao casereportresponsetocrizotinibtreatmentinapatientwithadvancednonsmallcelllungcancerwithldlrros1fusion AT junchen casereportresponsetocrizotinibtreatmentinapatientwithadvancednonsmallcelllungcancerwithldlrros1fusion AT jingli casereportresponsetocrizotinibtreatmentinapatientwithadvancednonsmallcelllungcancerwithldlrros1fusion AT jingli casereportresponsetocrizotinibtreatmentinapatientwithadvancednonsmallcelllungcancerwithldlrros1fusion |